Last reviewed · How we verify
Angiomax (bivalirudin)
Bivalirudin is a direct thrombin inhibitor that binds to and blocks thrombin, preventing blood clot formation.
Bivalirudin is a direct thrombin inhibitor that binds to and blocks thrombin, preventing blood clot formation. Used for Anticoagulation during percutaneous coronary intervention (PCI), Acute coronary syndrome (ACS) in patients undergoing PCI.
At a glance
| Generic name | Angiomax (bivalirudin) |
|---|---|
| Sponsor | The Medicines Company |
| Drug class | Direct thrombin inhibitor |
| Target | Thrombin (Factor IIa) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Bivalirudin is a synthetic peptide that directly inhibits thrombin (Factor IIa), a key enzyme in the coagulation cascade responsible for converting fibrinogen to fibrin and activating platelets. Unlike heparin, which requires antithrombin III as a cofactor, bivalirudin binds directly to both the active site and exosite I of thrombin, providing rapid and predictable anticoagulation. It is used during percutaneous coronary intervention to prevent thrombotic complications.
Approved indications
- Anticoagulation during percutaneous coronary intervention (PCI)
- Acute coronary syndrome (ACS) in patients undergoing PCI
Common side effects
- Bleeding
- Thrombocytopenia
- Hypotension
- Dyspnea
Key clinical trials
- Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes (PHASE4)
- Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System (PHASE2)
- A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction (NA)
- Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation (NA)
- Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI (NA)
- A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation. (PHASE4)
- Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation
- Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Angiomax (bivalirudin) CI brief — competitive landscape report
- Angiomax (bivalirudin) updates RSS · CI watch RSS
- The Medicines Company portfolio CI